These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Dendritic cell engineered cTXN as new vaccine prospect against L. donovani. Suman SS; Kumar A; Singh AK; Amit A; Topno RK; Pandey K; Das VNR; Das P; Ali V; Bimal S Cytokine; 2021 Sep; 145():155208. PubMed ID: 32736961 [TBL] [Abstract][Full Text] [Related]
13. Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis. Baharia RK; Tandon R; Sharma T; Suthar MK; Das S; Siddiqi MI; Saxena JK; Sundar S; Dube A PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003557. PubMed ID: 25745863 [TBL] [Abstract][Full Text] [Related]
14. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Bhowmick S; Ravindran R; Ali N Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029 [TBL] [Abstract][Full Text] [Related]
15. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis. Jaiswal AK; Khare P; Joshi S; Kushawaha PK; Sundar S; Dube A PLoS One; 2014; 9(9):e108556. PubMed ID: 25268700 [TBL] [Abstract][Full Text] [Related]
16. Visceral leishmaniasis: A novel nuclear envelope protein 'nucleoporins-93 (NUP-93)' from Leishmania donovani prompts macrophage signaling for T-cell activation towards host protective immune response. Singh MK; Jamal F; Dubey AK; Shivam P; Kumari S; Pushpanjali ; Bordoloi C; Narayan S; Das VNR; Pandey K; Das P; Singh SK Cytokine; 2019 Jan; 113():200-215. PubMed ID: 30001865 [TBL] [Abstract][Full Text] [Related]
17. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate. Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653 [TBL] [Abstract][Full Text] [Related]
18. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice. Dey R; Dagur PK; Selvapandiyan A; McCoy JP; Salotra P; Duncan R; Nakhasi HL J Immunol; 2013 Mar; 190(5):2138-49. PubMed ID: 23338240 [TBL] [Abstract][Full Text] [Related]
19. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803 [TBL] [Abstract][Full Text] [Related]
20. Genetically Engineered Ascorbic acid-deficient Live Mutants of Leishmania donovani induce long lasting Protective Immunity against Visceral Leishmaniasis. Anand S; Madhubala R Sci Rep; 2015 Jun; 5():10706. PubMed ID: 26035062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]